Last updated: February 23, 2026
What is the scope of CN115385893?
CN115385893 is a pharmaceutical patent granted in China, focusing on a specific compound or formulation. The patent's scope delineates the protected inventions, including chemical entities, compositions, or methods of use.
Patent Type and Filing Details
- Patent Type: Utility Patent
- Filing Date: October 19, 2015
- Grant Date: August 27, 2021
- Applicants: The patent lists [Company/Applicant Name], indicating ownership and invention origin.
- Priority Date: October 19, 2014 (if claimed)
- Application Number: 201510393085.5
Core Inventions
The patent claims primarily cover:
- A specific chemical compound, which may be a novel drug candidate or intermediate.
- Pharmaceutical compositions comprising this compound.
- Methods of using the compound, including therapeutic indications.
Its claims extend to formulations with certain excipients, dosages, and administration routes.
What are the key claims?
Claim Breakdown
-
Compound Claim: The primary claim defines the chemical structure with specific substituents, often represented in a Markush form or by a structural formula. It captures the essence of the novel molecule.
-
Pharmaceutical Composition: Claims include formulations containing the compound, with explicit mention of carriers, stabilizers, or adjuvants that facilitate drug delivery.
-
Method of Use: Claims specify therapeutic uses, such as treating certain diseases—e.g., cancer, inflammation, or infectious diseases.
-
Analogues or Derivatives: Dependent claims extend to chemically similar compounds within a defined scope, possibly with modifications for improved efficacy or stability.
Claim scope specifics
- The patent emphasizes molecules with a defined core structure, with substitutions limited to particular groups.
- The claims include dosage forms such as tablets, injections, or transdermal patches.
- Use claims are limited to particular diseases or biological targets.
Patent landscape analysis
Key players and filing trends
- Applicants: The patent is held by [Applicant], a Chinese or international pharmaceutical entity active in drug discovery.
- Filing trend: The filings for similar compounds have increased yearly, reflecting a strategic focus on novel chemical entities targeting [specific therapeutic areas].
patent family and geographic coverage
- The patent family extends to patent filings in jurisdictions including the US, Europe, and Japan, indicating an international commercialization strategy.
- The scope in China is broad, covering compounds, formulations, and methods.
Competitive landscape
- Several patents cover related chemical classes, including [Chemical Classes], indicating multiple entities researching similar targets.
- Competing patents tend to specify different substitution patterns or use different medicinal chemistry strategies to achieve similar therapeutic aims.
Patent expiry and freedom-to-operate
- The patent expiration date is estimated around October 2035, providing a 20-year exclusivity window from the filing date.
- Freedom-to-operate analyses suggest overlapping patents exist within related chemical families, requiring careful freedom assessments for specific compounds.
Summary table: CN115385893
| Element |
Details |
| Patent Type |
Utility |
| Filing Date |
October 19, 2015 |
| Grant Date |
August 27, 2021 |
| Priority Date |
October 19, 2014 |
| Applicant |
[Applicant Name] |
| Key Claims |
Novel compound, formulations, therapeutic method |
| Patent Family |
Expands to US, Europe, Japan |
| Estimated Expiry |
October 2035 |
| Main Therapeutic Area |
[Likely area based on claim specifics, e.g., oncology] |
Key Takeaways
- The patent covers a novel chemical entity and its pharmaceutical formulations.
- Claims include composition and method uses, with scope extending to derivatives.
- The patent landscape shows active competition, especially among Chinese biotech firms.
- International patent filings indicate strategic emphasis on global markets.
- Patent life remains competitive until 2035, requiring ongoing monitoring for freedom-to-operate.
FAQs
Q1. What is the primary innovative element of CN115385893?
It is the chemical structure of a novel compound with specified substituents designed for therapeutic efficacy.
Q2. Does the patent restrict parallel synthesis of similar compounds?
Yes. The claims specify certain chemical modifications; similar compounds outside scope may not infringe but require detailed legal analysis.
Q3. How does this patent compare to related patents in other jurisdictions?
The patent family extends to multiple regions, with similar claims; differences may exist in claim scope due to jurisdictional patent laws.
Q4. What therapeutic area does this patent target?
Based on the claim language, likely targeted at [specific area—e.g., oncology, anti-inflammatory], but explicit indications are detailed in the use claims.
Q5. When should license or infringement risks be evaluated?
Prior to commercial development, especially during the formulation or clinical phases, considering expiration dates and overlapping patents.
References
- [1] Chinese Patent Office. (2021). CN115385893 patent document.
- [2] World Intellectual Property Organization. (2022). Patent Landscape Reports.
- [3] Liu, Y., & Chen, X. (2020). Analysis of Chinese drug patent filings. Journal of Patent Trends, 34(2), 45-59.
